Use of medroxyprogesterone acetate in women with ovarian endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization
- PMID: 28931865
- PMCID: PMC5607235
- DOI: 10.1038/s41598-017-12151-7
Use of medroxyprogesterone acetate in women with ovarian endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization
Abstract
This study investigated the use of medroxyprogesterone acetate (MPA) or a short protocol for controlled ovarian hyperstimulation (COH) in patients with advanced endometriosis who have normal ovarian function, and to compare cycle characteristics and pregnancy outcomes after frozen-thawed embryo transfer (FET). This was a retrospective case-control study of 244 patients with advanced endometriosis undering COH. The patients were allocated to three groups: the surgery group with MPA COH (62 patients, 71 IVF/ICSI cycles, 78 FET cycles); the aspiration group with MPA COH (85 patients had ovarian "chocolate" cysts (>3 cm) aspirated, 90 IVF/ICSI cycles, 76 FET cycles); and the short protocol group (97 patients, 101 IVF/ICSI cycles, 51 FET cycles). The results showed that higher rates of mature oocyte, D3 high quality embryo, hMG dose were observed in the two study groups using MPA compared with the short protocol. The number of >10-14 mm follicles on the trigger day, D3 top-quality embryos, viable embryos, rates of cancellation, fertilization, implantation, pregnancy outcomes were similar among the three groups. The oocytes, embryos, and pregnancy outcomes were not influenced by endometrioma surgery or presence of endometrioma. MPA COH could be effective for women with ovarian advanced endometriosis who had normal ovarian function.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures


Similar articles
-
Impacts of medroxyprogesterone acetate on oocytes and embryos: matched case-control study in women with stage III-IV ovarian endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization.Ann Transl Med. 2020 Mar;8(6):377. doi: 10.21037/atm.2020.02.15. Ann Transl Med. 2020. PMID: 32355821 Free PMC article.
-
Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.Fertil Steril. 2015 Jul;104(1):62-70.e3. doi: 10.1016/j.fertnstert.2015.03.022. Epub 2015 May 5. Fertil Steril. 2015. PMID: 25956370 Clinical Trial.
-
New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.Hum Reprod. 2018 Feb 1;33(2):229-237. doi: 10.1093/humrep/dex367. Hum Reprod. 2018. PMID: 29300975 Clinical Trial.
-
In vitro fertilization for endometriosis-associated infertility.Womens Health (Lond). 2015 Aug;11(5):633-41. doi: 10.2217/whe.15.50. Epub 2015 Sep 23. Womens Health (Lond). 2015. PMID: 26395161 Review.
-
[Medroxyprogesteron acetate use to block LH surge in oocyte donor stimulation].Ceska Gynekol. 2018 Winter;83(1):11-16. Ceska Gynekol. 2018. PMID: 29510633 Review. Czech.
Cited by
-
Metabolomics analysis of follicular fluid in ovarian endometriosis women receiving progestin-primed ovary stimulation protocol for in vitro fertilization.Sci Rep. 2023 Apr 7;13(1):5747. doi: 10.1038/s41598-023-32797-w. Sci Rep. 2023. PMID: 37029234 Free PMC article.
-
Impacts of medroxyprogesterone acetate on oocytes and embryos: matched case-control study in women with stage III-IV ovarian endometriosis undergoing controlled ovarian hyperstimulation for in vitro fertilization.Ann Transl Med. 2020 Mar;8(6):377. doi: 10.21037/atm.2020.02.15. Ann Transl Med. 2020. PMID: 32355821 Free PMC article.
-
Anti-müllerian Hormone for the Prediction of Ovarian Response in Progestin-Primed Ovarian Stimulation Protocol for IVF.Front Endocrinol (Lausanne). 2019 May 28;10:325. doi: 10.3389/fendo.2019.00325. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31191453 Free PMC article.
-
Recent Trends in Medical Management of Endometriosis.J Obstet Gynaecol India. 2024 Dec;74(6):479-483. doi: 10.1007/s13224-024-02097-y. Epub 2024 Dec 26. J Obstet Gynaecol India. 2024. PMID: 39758571
-
Progestin-primed ovarian stimulation (PPOS) in preimplantation genetic testing for aneuploidy: a retrospective study and meta-analysis.Arch Gynecol Obstet. 2025 Apr;311(4):1181-1193. doi: 10.1007/s00404-024-07918-z. Epub 2025 Feb 13. Arch Gynecol Obstet. 2025. PMID: 39945792 Free PMC article. Review.
References
-
- Baldi A, Campioni M, Signorile PG. Endometriosis: pathogenesis, diagnosis, therapy and association with cancer (review) Oncol Rep. 2008;19:843–846. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical